HCPCS Level II code J1553 denotes a 100 mg injection of immune globulin branded as yimmugo. This code identifies a specific biologic therapy used for immune support or replacement and is relevant for infusion and specialty drug billing nationwide. Accurate coding of J1553 matters for clinical documentation, pharmacy and infusion reimbursement, and supply chain tracking for biologic immunoglobulin products.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides national benchmarks and coding context relevant to these payers, summarizes clinical indications tied to immune globulin therapy, and highlights how this HCPCS Level II drug code fits into billing workflows for infusion centers, hospital outpatient departments, and physician offices.

Readers will learn the code definition and typical sites of service, payer coverage considerations, common claim line practices, and related billing topics. Where input data is missing, the report notes that specific fields are unavailable. The focus is operational clarity for revenue cycle, clinical administrators, and policy analysts handling biologic immunoglobulin administration coded with J1553.